February 26, 2020 / 6:05 PM / a month ago

BRIEF-Abivax: First Patient In ABX196 Trial For Hepatocellular Carcinoma Treatment

Feb 26 (Reuters) - ABIVAX SA:

* ABIVAX INCLUDES FIRST PATIENT IN U.S. PHASE 1/2 CLINICAL TRIAL OF ABX196 TO TREAT HEPATOCELLULAR CARCINOMA

* FIRST PATIENT DOSED WITH ABX196, AN INKT (INVARIANT NATURAL KILLER T CELL) AGONIST, IN COMBINATION WITH NIVOLUMAB

* PHASE 1/2 STUDY TO EVALUATE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF COMBINATION THERAPY

* STUDY’S OBJECTIVE IS TO GENERATE INITIAL DATA ABOUT SAFETY AND TOLERABILITY OF THIS NOVEL COMBINATION TREATMENT Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below